samedan logo
 
 
 
spacer
home > ebr > summer 2021 > bio-europe® 2021 digital
PUBLICATIONS
European Biopharmaceutical Review

BIO-Europe® 2021 Digital

EBR: What lessons did you learn from BIO-Europe Digital 2020, and how have those findings reflected upon the decisions taken in relation to BIO-Europe 2021?

Pam Putz: BIO-Europe Digital 2020 was a remarkable success and proved that digital partnering is an effective tool during this crisis to keep the deal flow going. As we started to plan for this year’s edition, we factored in feedback from all our international stakeholders: small biotechs that look for a high ROI on their partnering meetings, pharma companies and other large players with yet to be lifted travel restrictions, our host, and other economic development groups we partner with.

Thankfully, we also have strong data points to guide our decision: we know that two-thirds of all meetings that take place at BIO-Europe involve at least one attendee from North America, Asia, or Australia. Our mission with BIO-Europe has always focused on connecting the international life science community, and the unique value we provide is to meet the world at BIO-Europe in three days. Factoring in what we have learned over the last 18 months, we have come to the decision that we can best meet the needs of the global life science community in a virtual setting.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
Pam Putz is Managing Director at EBD Group.

Our mission with BIO-Europe has always focused on connecting the international life science community, and the unique value we provide is to meet the world at BIO-Europe during a three day event and we’ll do it again later this year, over four days, 25-28 October, 2021.
spacer
Pam Putz
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Nemera reinforces its value proposition with a refreshing visual identity

At Nemera, we have been successfully providing high quality drug delivery device solutions to our customers and patients for years. We design and manufacture devices with the ultimate goal to improve patient outcomes and experience.
More info >>

White Papers

Key to Outsourcing Method Development and Validation A Pragmatic Approach

RSSL

In an industry that is seeing an increasing level of work being outsourced, the Contract Research Organisation (CRO) of choice needs to have proven experience in both the pragmatism and flexibility of the method developer’s mind set and a regulatory background in validation.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement